Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell. It is a substituted benzimidazole sulfoxide prodrug that is activated in the acidic environment of the parietal cell canaliculus. It is widely used for the management of acid-related disorders in the Indian population, known for its good safety profile and predictable pharmacokinetics.
Adult: GERD/Erosive Esophagitis: 40mg once daily for 4-8 weeks. Maintenance: 40mg once daily. Peptic Ulcer: 40mg once daily for 4-8 weeks. H. pylori Eradication: 40mg twice daily as part of combination therapy (e.g., with Amoxicillin 1g and Clarithromycin 500mg twice daily for 14 days). Hypersecretory conditions: Starting dose 40mg twice daily, titrated based on acid output.
Note: Swallow the tablet whole with water, preferably in the morning before breakfast. Do not crush, chew, or split the enteric-coated tablet. Can be taken without regard to meals, but morning dosing provides better control of daytime acidity.
Pantoprazole is a prodrug. In the acidic environment of the parietal cell canaliculus, it is converted to its active form, a cyclic sulfenamide. This active metabolite forms covalent disulfide bonds with cysteine residues (Cys813 and Cys822) on the alpha subunit of the H+/K+ ATPase enzyme (the proton pump), irreversibly inhibiting its function. This prevents the final step of gastric acid secretion, the exchange of intracellular H+ for luminal K+.
Pregnancy: Pregnancy Category B (US FDA). Animal studies have shown no direct harm, but adequate and well-controlled studies in pregnant women are lacking. Should be used during pregnancy only if clearly needed, after consulting a physician. Indian guidelines recommend caution.
Driving: Pantoprazole is unlikely to affect the ability to drive and use machines. However, if dizziness or visual disturbances occur, patients should avoid these activities.
| Atazanavir, Nelfinavir (HIV Protease Inhibitors) | Significantly reduced absorption and plasma concentration due to increased gastric pH. | Major |
| Ketoconazole, Itraconazole, Posaconazole | Reduced absorption of these azole antifungals due to decreased solubility at higher pH. | Moderate |
| Methotrexate (especially high-dose) | May decrease renal clearance of methotrexate, potentially increasing toxicity. | Moderate |
| Warfarin | Potential for increased INR and risk of bleeding due to possible interaction via CYP2C19. Monitor INR closely. | Moderate |
| Clopidogrel | Theoretical interaction due to competition for CYP2C19 metabolism, potentially reducing clopidogrel's antiplatelet effect. Clinical significance is debated; pantoprazole may have a lower risk than omeprazole. | Moderate |
| Digoxin | May increase bioavailability of digoxin slightly. | Minor |
| Iron Salts (Ferrous Sulfate) | Reduced absorption of iron due to decreased gastric acidity. Separate administration by 2-4 hours. | Moderate |